I also think they would have sold quite a few other products in the likes of Fillerina. But as long as it's a profitable undertaking overall, I don't really care how much of the revenue Fillerina accounts for. It should add to Advangen's profitability and help promote evolis professional, and that's all that matters.
Regarding the timing, I believe that Fillerina sales would not do anything much to the June quarterly results yet. I would expect them so start showing in the September or December quarter. That's because the distribution switch over to Cellmid might take a while. Even if initial sales came in before July, I think we should not expect them to be significant for now. I don't mind if Advangen proves me wrong though.
CDY Price at posting:
46.5¢ Sentiment: Buy Disclosure: Held